Published on
October 23, 2022
- 23:05 GMT
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual ...
– Investigational oral microbiome therapeutic was observed to reduce recurrent C. difficile infection (rCDI) after just one recurrence and remained low regardless of diagnostic approach – – Clinical data shows SER-109 is well tolerated, including among …
Distribution channels:
Banking, Finance & Investment Industry
